Paysign FY2023 revenue up 24% to $47.3M; net income $6.5M; guides FY2024 revenue $54.5-56.7M

Paysign, Inc.

Full-year 2023 total revenue $47.3M (+24% YoY); net income $6.5M ($0.12 diluted EPS) vs $1.0M ($0.02) in 2022.
Adjusted EBITDA $6.7M (+21% YoY); Q4 2023 revenue $13.7M (+29% YoY), net income $5.6M ($0.10 diluted EPS).
Plasma centers up 20 net to 464; pharma patient affordability programs up 24 net to 43; revenue from pharma patient affordability +172% YoY.
Exited FY2023 with $17.0M unrestricted cash, zero debt; repurchased 394,558 shares for $1.1M.
FY2024 guidance: revenue $54.5-56.7M, net income $2-3M ($0.04-0.06 diluted EPS), adjusted EBITDA $8-9M ($0.15-0.17 diluted EPS).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Paysign, Inc. reported the fiscal year ended December 31, 2023 results: revenue $47.3 million, net income $6.5 million, EPS $0.12.

Period: the fiscal year ended December 31, 2023
Revenue: $47.3 million
Net income: $6.5 million
EPS: $0.12
Result: reported results

Exact text from the filing

PRESS RELEASE Exhibit 99.1 Earnings Release Paysign, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results For the Full Year · Full-year 2023 total revenues of $47.3 million, up 24% from full-year 2022 · Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.